Related Experiment Video
Updated: Jun 23, 2025
Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures
Published on: March 12, 2018
How much protection does clopidogrel provide to cats with hypertrophic cardiomyopathy?
Insights
Clopidogrel may reduce the risk of aortic thromboembolism (ATE) in cats with hypertrophic cardiomyopathy (HCM) by 3-4%. However, due to administration challenges and small benefits, its routine use as a preventative is questionable.
Area of Science:
- Veterinary Cardiology
- Pharmacology
- Internal Medicine
Background:
- Hypertrophic cardiomyopathy (HCM) in cats increases the risk of aortic thromboembolism (ATE).
- Clopidogrel is effective in preventing ATE recurrence after an initial episode.
- Current recommendations suggest primary ATE prevention with clopidogrel for cats with severe HCM.
Purpose of the Study:
- To estimate the potential benefit of clopidogrel for primary prevention of ATE in cats with moderate to severe HCM.
- To aid clinicians in determining the necessity of clopidogrel treatment on a case-by-case basis.
- To inform the risk-benefit analysis of clopidogrel administration in feline cardiology.
Main Methods:
- Statistical analysis of existing data.
- Incorporation of assumptions and extrapolations to estimate risk reduction.
- Calculation of relative and absolute risk reduction for ATE.
Main Results:
- Clopidogrel administration is estimated to confer a 3% to 4% reduction in ATE risk for cats with moderate to severe HCM.
- The drug's unpalatability presents significant administration challenges for cat owners.
- The estimated risk reduction is relatively small, necessitating careful consideration.
Conclusions:
- The decision to administer clopidogrel for primary ATE prevention in cats with HCM should be individualized.
- Clinicians must weigh the modest potential benefits against the practical difficulties and owner burden of administration.
- Routine mandatory administration of clopidogrel for primary prevention may not be warranted for all cats with severe HCM.
Abstract:
Cats with hypertrophic cardiomyopathy (HCM) have a risk of developing aortic thromboembolism (ATE). Clopidogrel reduces the risk of redeveloping ATE and delays recurrence of ATE in cats that have experienced an ATE episode. Consequently, cardiologists have recommended administering clopidogrel to cats as a primary preventative, suggesting that all cats with severe HCM be administered clopidogrel. However, clopidogrel is unpalatable in its manufactured format, making such administration problematic for many clients. Therefore, estimating the potential benefit of administration might help clinicians determine on a case-by-case basis the need to treat cats with clopidogrel. Relatively simple statistical analyses of currently available data, along with certain assumptions and extrapolations, allow such an estimation of benefit in terms of relative and absolute risk reduction conferred by clopidogrel. Using this approach, and provided certain assumptions are true, clopidogrel likely confers a reduction in risk of ATE in cats with moderate to severe HCM of approximately 3% to 4%. Given the difficulty of administering clopidogrel to cats, clinicians should weigh these relatively small potential benefits against the potential harms (difficulty of administration) and not necessarily insist that clients administer clopidogrel.
